TEMAI diagnostics and health data
Tempus AI
- Price
- $54.04
- Intrinsic value
- Intrinsic value from an AI estimate
- Discount category
- Close to intrinsic value (AI estimate)
- Analysts
- Leaning bullish
- Next earnings
- Feb 2 · · estimated
- Pick status
- Research only
In short
- Thesis
- Investors pay a premium for the fast growth of Tempus AI in cancer tests and data licenses, and only several years of strong growth with rising profits can earn this price.
- Gap
- Slow. The price asks for several years of fast growth and rising profits, so only results through 2027 and later can show if Tempus earns it.
Company guidance: 2026 revenue $1.60 to $1.605 billion; adjusted EBITDA ~$65 million (, Q3 2026 results release (8-K))
Price history
About
Tempus AI, Inc. (TEM) is based in Chicago, Illinois. It uses AI and a large library of de-identified clinical and molecular data for precision medicine. Its Diagnostics business runs genomic tests for cancer, such as tumor profiling and minimal residual disease (MRD) tests, and hereditary tests. Its Data and Applications business licenses data and AI models to pharmaceutical companies and sells AI tools for doctors, such as algorithms for the ECG with FDA clearance.
In 2025, revenue was $1,271.8 million: Diagnostics gave $955.4 million and Data and Applications $316.4 million. The Class A common stock trades on Nasdaq in US dollars, and each Class B share converts into one Class A share. Tempus files 10-K and 10-Q reports.
Thesis
The price of Tempus AI depends on how fast its test volumes and data licenses grow and on when it earns a GAAP profit. In Q3 2026, revenue grew 23%, oncology volume grew 32%, Data and Applications revenue grew 33% and adjusted EBITDA was $25.6 million. Investors pay a high multiple of revenue because they see Tempus as an AI and data company, and the AI estimate gives less value because most revenue still comes from tests that payers reimburse, net losses continue and stock-based compensation is large. For the AI estimate to rise toward the price, three things must be true.
Revenue must grow by about 20% or more a year after 2026, from the 2026 guidance of $1.60 billion to $1.605 billion. Adjusted EBITDA must grow well above the guided $65 million for 2026, and GAAP losses must end. Data licensing bookings, more than $550 million so far in 2026, must turn into revenue. The vote of Personalis stockholders on November 30, 2026, the Q4 2026 report, expected in early February 2027, and results through 2027 are the next tests.
Valuation
AI estimate, checked by Kevin. How it is made
Show the method
The intrinsic value for Tempus AI is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Tempus AI with the SEC. The pick is the Class A common stock on Nasdaq.
Each Class B share converts into one Class A share, so the estimate counts both classes as one. The method is a multiple of 2027 revenue, less net debt, divided by the shares and unvested equity awards. The Q4 2025 release (8-K, February 24, 2026) gives 2025 revenue of $1,271.8 million and an adjusted EBITDA loss of $7.4 million. The Q3 2026 release (8-K, November 2, 2026) gives Q3 revenue of $411.5 million, up 23%, adjusted EBITDA of $25.6 million, a net loss of $14.9 million, and cash and marketable securities of $854.4 million.
It raises 2026 revenue guidance to $1.60 billion to $1.605 billion and expects adjusted EBITDA of about $65 million. The Form 10-Q for the quarter ended September 30, 2026 gives $750.0 million of 0.75% convertible senior notes due 2030, $460.0 million of 0.00% convertible senior notes due 2032 and a convertible promissory note carried at $176.0 million, so net debt is $531.6 million. The estimate counts the notes as debt at their principal and leaves out the capped calls, which is an assumption. The cover of the 10-Q gives 177,357,848 Class A shares and 5,043,789 Class B shares at October 29, 2026, and the 10-Q gives 5,931,276 unvested restricted stock units, 7,601 restricted stock awards and 1,929,552 performance stock units at September 30, 2026.
The estimate thus uses 190.27 million shares. Stock-based compensation was $154.9 million in nine months, and the estimate counts it through the units and the multiples, which is an assumption. The pending purchase of Personalis for $16.25 per share, mostly in Class A shares, is left out, and the estimate assumes that it neither adds nor removes value per share, which is an assumption. The 2027 revenue and the multiples are assumptions.
The low case assumes $1,840 million, because test volumes and data licenses grow more slowly, at 3.5 times revenue. It gives $31.05 per share. The base case assumes $1,960 million, or growth of about 22%, at 5.5 times. It gives $53.86 per share.
The high case assumes $2,080 million, from fast growth in MRD tests and data licensing, at 8 times. It gives $84.66 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $55.86 per share.
Tempus has a large library of clinical and molecular data and links with many oncologists, which helps its data licensing, but many laboratories sell similar genomic tests, and payers set much of the price.
Checkpoints
- Nov 30, 2026PendingPersonalis stockholder votePersonalis stockholders approve the merger and the deal closes in Q4 2026, and this passes; a failed vote or an end of the agreement fails.
- Feb 2, 2027 · est.PendingQ4 2026 results2026 revenue is in the guided range of $1.60 billion to $1.605 billion, adjusted EBITDA is about $65 million or more, and the 2027 outlook gives growth of about 20% or more, and this passes; lower growth or a weaker outlook fails.
Recent events
- November 2, 2026Tempus reported Q3 2026 results. Revenue rose 23% to $411.5 million, Diagnostics revenue rose 20% and Data and Applications revenue rose 33%. The net loss was $14.9 million and adjusted EBITDA was $25.6 million. It raised its 2026 revenue guidance to $1.60 billion to $1.605 billion. It also said that a collaboration with BMS in October brought its data licensing bookings to more than $550 million in 2026.
- July 30, 2026Tempus reported Q2 2026 results. Revenue rose 22% to $382.5 million, GAAP net income was $5.6 million and adjusted EBITDA was $8.0 million. The FDA approved its xT Tumor Only test.
- July 20, 2026Tempus agreed to buy the shares of Personalis that it does not already own for $16.25 per share, mostly in Class A shares, an enterprise value of $1.5 billion. Personalis can end the agreement if the average price of Tempus shares before the closing is below $46.00.
Show 3 older eventsHide older events
- May 12, 2026Tempus sold $460.0 million of 0.00% Convertible Senior Notes due 2032, with a conversion price of about $69.26, for net proceeds of $442.0 million.
- May 5, 2026Tempus reported Q1 2026 results with revenue of $348.1 million and a net loss of $125.9 million.
- February 24, 2026Tempus reported 2025 results. Revenue rose 83.4% to $1,271.8 million, the net loss was $245.0 million and the adjusted EBITDA loss was $7.4 million. It guided 2026 revenue of $1.59 billion and adjusted EBITDA of about $65 million.
Latest news and filings
- Last earnings
- November 2, 2026 (8-K on sec.gov)
- Next earnings
- Expected about February 2, 2027. The company has not confirmed the date.
- 10-QQuarterly report for the period ended Sep 30, 2026Filed tem-20260930
- 8-KEarnings release and Investor disclosureFiled Press release and exhibits
- 8-KOther company newsFiled Read it on sec.gov
- 10-QQuarterly report for the period ended Jun 30, 2026Filed tem-20260630
- 8-KEarnings release and Investor disclosureFiled Press release and exhibits
- 8-KNew material agreementFiled Read it on sec.gov
- 8-KInvestor disclosureFiled Read it on sec.gov
- 8-KShareholder vote resultsFiled Read it on sec.gov
- 8-KNew material agreement and End of a material agreementFiled Read it on sec.gov
- 10-QQuarterly report for the period ended Mar 31, 2026Filed tem-20260331
Risks
- Most Diagnostics revenue depends on payment from Medicare, Medicaid and commercial insurers. At December 31, 2025, Tempus had received payment on about 55% of its clinical oncology tests. Lower prices or less coverage can cut revenue.
- Tempus still has net losses, and stock-based compensation was $154.9 million in the first nine months of 2026. The convertible notes and equity awards can add about 23.4 million shares.
- The purchase of Personalis is paid mostly in shares and can still fail. The integration of Personalis and of earlier purchases, such as Ambry Genetics and Paige, can cost more than planned.
- Data licensing depends on large multi-year agreements with a few pharmaceutical companies, such as AstraZeneca and Pathos, and a contract can end or be delayed.
- Many laboratories sell similar genomic and MRD tests, and new rules from the FDA for laboratory tests can raise costs.
Key statistics
- Market cap
- $9.9B
- Shares of Oct 29, 2026
- EPS (trailing)
- -$1.06
- 12 months to Sep 30, 2026
- 52-week range
- $40.77 – $89.09
- To Nov 13, 2026
- Average volume
- 7.4M
- 3 months, to Nov 13, 2026
Check the numbers:ExchangeGoogle FinanceYahoo FinanceSEC filings
Balance sheet
- Cash
- $854M
- Debt
- $1.4B
- Net debt
- $532M
Cash against debt
debt covered by cashnet debt $532M
At September 30, 2026, Tempus had cash and marketable securities of $854.4 million, of which cash and cash equivalents were $590.5 million. Debt was $750.0 million of 0.75% Convertible Senior Notes due 2030, with a conversion price of about $84.19, $460.0 million of 0.00% Convertible Senior Notes due 2032, with a conversion price of about $69.26, and a convertible promissory note carried at $176.0 million. Capped calls reduce the dilution from the notes. In 2026, Tempus repaid its long-term debt of $202.8 million and its revolving credit facility of $100.0 million.
Dividends
Tempus AI does not pay a dividend.
Source: company filings and market data, read on November 13, 2026.
Questions about Tempus AI
What does Tempus AI do?
Tempus AI, Inc. (TEM) is based in Chicago, Illinois. It uses AI and a large library of de-identified clinical and molecular data for precision medicine. Its market cap is $9.9B at the current price of $54.04.
When does Tempus AI report earnings next?
This is an estimate: Tempus AI may report on February 2, 2027. It last reported results on November 2, 2026.
Is Tempus AI stock below its intrinsic value?
Tempus AI stock is close to intrinsic value. The source of the intrinsic value is: AI estimate. This is general information, not advice.
What changed recently at Tempus AI?
The latest update is from November 2, 2026. Tempus reported Q3 2026 results.
What are the main risks for Tempus AI?
Most Diagnostics revenue depends on payment from Medicare, Medicaid and commercial insurers. Tempus still has net losses, and stock-based compensation was $154.9 million in the first nine months of 2026. The purchase of Personalis is paid mostly in shares and can still fail.
How much debt and cash does Tempus AI have?
At September 30, 2026, Tempus AI had $1.4B of debt and $854M of cash.
Does Tempus AI pay a dividend?
No. Tempus AI does not pay a dividend.
Valuation against peers
| Company | P/E, last 4 quarters | EV/EBITDA, last year | Free cash flow yield, last year | 10-year average P/E |
|---|---|---|---|---|
| TEMTempus AI | n/a | n/a | -2.4% | n/a |
| VRSKVerisk | 30.6x | n/a | 4.6% | 38.7x |
| APPAppLovin | 23.5x | n/a | n/a | n/a |
| INTUIntuit | 16.4x | n/a | 12.0% | 46.0x |
| BRBroadridge Financial Solutions | 20.1x | 16.4x | 6.2% | 29.4x |
| Peer median | 21.8x | n/a | 6.2% | n/a |
- Its free cash flow yield is -2.4%, 8.7 points below the peer median of 6.2%.
The peers are the companies on this site most like TEM. The multiples come from company filings and today's price. There are no analyst forecasts: they all look back. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.
Similar companies
- EXPGYExperianShares: AI disruption risk, Regulation and courts
- Intrinsic value
- Far below intrinsic value
- Gap
- Slow
- VRSKVeriskShares: AI disruption risk, Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- SAPSAPShares: AI disruption risk, Regulation and courts
- Intrinsic value
- Far below intrinsic value
- Gap
- Can close
- APPAppLovinShares: Regulation and courts, AI disruption risk
- Intrinsic value
- Below intrinsic value
- Gap
- Can close
- INTUIntuitShares: AI disruption risk, Regulation and courts
- Intrinsic value
- Well below intrinsic value
- Gap
- Can close
Loading your notes…
Read it all? Star TEM or pass, then go on to the next one.